Growth Metrics

Edwards Lifesciences (EW) Cash from Operations (2016 - 2026)

Edwards Lifesciences has reported Cash from Operations over the past 17 years, most recently at 450900000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 453.65% year-over-year to 450900000.0; the TTM value through Dec 2025 reached 1595200000.0, up 194.15%, while the annual FY2025 figure was 1595200000.0, 194.15% up from the prior year.
  • Cash from Operations for Q4 2025 was 450900000.0 at Edwards Lifesciences, down from 573700000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 573700000.0 in Q3 2025 and troughed at 127500000.0 in Q4 2024.
  • A 5-year average of 299180000.0 and a median of 312000000.0 in 2022 define the central range for Cash from Operations.
  • On a YoY basis, Cash from Operations climbed as much as 1005.65% in 2024 and fell as far as 193.34% in 2024.
  • Year by year, Cash from Operations stood at 373600000.0 in 2021, then decreased by 24.3% to 282800000.0 in 2022, then tumbled by 51.7% to 136600000.0 in 2023, then crashed by 193.34% to 127500000.0 in 2024, then soared by 453.65% to 450900000.0 in 2025.
  • Business Quant data shows Cash from Operations for EW at 450900000.0 in Q4 2025, 573700000.0 in Q3 2025, and 290200000.0 in Q2 2025.